We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Ajinomoto Bio-Pharma Services, a biopharmaceutical CDMO, and Bright Peak Therapeutics Inc., a biotechnology company developing next gen immunotherapies for cancer and autoimmune disease, have entered a research collaboration and exclusive license ...